Literature DB >> 11344204

Effects of morning hypoglycemia on neuroendocrine and metabolic responses to subsequent afternoon hypoglycemia in normal man.

S N Davis1, D Tate.   

Abstract

There is general agreement that prior hypoglycemia blunts subsequent hypoglycemic counterregulatory responses. However, there is considerable debate concerning the timing and number of prior hypoglycemic episodes required to cause this blunting effect. The aim of this study was to determine whether one episode of hypoglycemia could modify neuroendocrine, metabolic, and symptom responses to hypoglycemia induced 2 h later. A total of 24 (12 male and 12 female) young, healthy, overnight-fasted subjects participated in a series of glucose clamp studies. A total of 16 individuals underwent 2 randomized studies of either identical 2-h morning and afternoon hyperinsulinemic (490 +/- 60 pmol/L) hypoglycemia (2.9 +/- 0.1 mmol/L) separated by 2 h or, at least 2 months later, 2-h morning and afternoon hyperinsulinemic (492 +/- 45 pmol/L) euglycemia (5.1 +/- 0.1 mmol/L). A total of 8 other subjects participated in a single experiment that consisted of 2-h morning hyperinsulinemic (516 +/- 60 pmol/L) euglycemia (5.1 +/- 0.1 mmol/L) and 2-h afternoon hyperinsulinemic (528 +/- 66 pmol/L) hypoglycemia (2.9 +/- 0.1 mmol/L) also separated by 2 h. Morning hypoglycemia significantly (P < 0.01) reduced (33-55%) the responses of epinephrine, norepinephrine, glucagon, GH, cortisol, and pancreatic polypeptide during afternoon hypoglycemia. Hypoglycemic symptoms (primarily neuroglycopenic) were also significantly (P < 0.01) reduced during afternoon hypoglycemia. Plasma glucose, insulin, nonesterified fatty acids, glycerol, lactate, beta-hydroxybutyrate (P < 0.01), GH, and cortisol (P < 0.05) levels were significantly increased at the start of afternoon hypoglycemia following morning hypoglycemia. Morning hypoglycemia created an insulin-resistant state during afternoon hypoglycemia. Despite blunted neuroendocrine responses, glucose infusion rates required to maintain hypoglycemia and increases in glucose oxidation were significantly attenuated during afternoon compared with morning hypoglycemia. This was in marked contrast to euglycemic control experiments where glucose infusion rates and nonoxidative glucose disposal were significantly increased during afternoon relative to morning studies. We conclude that in normal man one episode of prolonged, moderate, morning hypoglycemia can produce substantial blunting of neuroendocrine and symptomatic responses to subsequent near-term hypoglycemia, and the induction of posthypoglycemic insulin resistance can compensate for blunted neuroendocrine responses by limiting glucose flux and specifically glucose oxidation during subsequent near-term hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344204     DOI: 10.1210/jcem.86.5.7495

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Hypoglycemia-associated autonomic failure is prevented by opioid receptor blockade.

Authors:  James Leu; Min-Hui Cui; Harry Shamoon; Ilan Gabriely
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

2.  Antecedent hypoglycaemia does not diminish the glycaemia-increasing effect and glucoregulatory responses of a 10 s sprint in people with type 1 diabetes.

Authors:  Raymond J Davey; Nirubasini Paramalingam; Adam J Retterath; Ee Mun Lim; Elizabeth A Davis; Timothy W Jones; Paul A Fournier
Journal:  Diabetologia       Date:  2014-03-16       Impact factor: 10.122

Review 3.  Mechanisms of hypoglycemia and exercise-associated autonomic dysfunction.

Authors:  Stephen N Davis; Donna Tate; Maka S Hedrington
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

4.  Partial blockade of nicotinic acetylcholine receptors improves the counterregulatory response to hypoglycemia in recurrently hypoglycemic rats.

Authors:  Edmund F LaGamma; Necla Kirtok; Owen Chan; Bistra B Nankova
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-12       Impact factor: 4.310

5.  Exercise-related hypoglycemia in diabetes mellitus.

Authors:  Lisa M Younk; Maia Mikeladze; Donna Tate; Stephen N Davis
Journal:  Expert Rev Endocrinol Metab       Date:  2011-01-01

6.  Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis.

Authors:  Paola Lucidi; Paolo Rossetti; Francesca Porcellati; Simone Pampanelli; Paola Candeloro; Anna Marinelli Andreoli; Gabriele Perriello; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

7.  Hypoglycemia-associated autonomic failure in healthy humans: comparison of two vs three periods of hypoglycemia on hypoglycemia-induced counterregulatory and symptom response 5 days later.

Authors:  A Moheet; A Kumar; L E Eberly; J Kim; R Roberts; E R Seaquist
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

8.  Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.

Authors:  Emily G Hoffman; Mahsa Jahangiriesmaili; Erin R Mandel; Caylee Greenberg; Julian Aiken; Ninoschka C D'Souza; Aoibhe Pasieka; Trevor Teich; Owen Chan; Richard Liggins; Michael C Riddell
Journal:  Endocrinology       Date:  2021-12-01       Impact factor: 5.051

9.  Whole genome expression profiling associates activation of unfolded protein response with impaired production and release of epinephrine after recurrent hypoglycemia.

Authors:  Juhye Lena Kim; Edmund F La Gamma; Todd Estabrook; Necla Kudrick; Bistra B Nankova
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

10.  Opioid Receptor Activation Impairs Hypoglycemic Counterregulation in Humans.

Authors:  Michelle Carey; Rebekah Gospin; Akankasha Goyal; Nora Tomuta; Oana Sandu; Armand Mbanya; Eric Lontchi-Yimagou; Raphael Hulkower; Harry Shamoon; Ilan Gabriely; Meredith Hawkins
Journal:  Diabetes       Date:  2017-08-31       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.